Cardiomyopathy Trial, Recruiting NCT06356727 Sponsor: Azienda Ospedaliera Universitaria Integrata Verona Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT06356727
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults (male or female) aged 18 or older
  • People who have recently been diagnosed for the first time with a type of heart condition called idiopathic dilated cardiomyopathy (a weakened, enlarged heart with no known cause), where the heart's pumping function is significantly reduced (confirmed by specific measurements), and where doctors have already recommended a procedure to check the heart's arteries
  • People who are willing and able to agree to participate by signing a consent form

Who may not be able to join:

  • People found to have significantly blocked heart arteries (confirmed during the artery-checking procedure using specific measurement methods)
  • People with a previous history of heart attack, or who have had a procedure or surgery to open or bypass blocked heart arteries
  • People with serious heart valve problems (such as rheumatic heart disease, or severe narrowing or leaking of the aortic or mitral valves)
  • People with an active infection of the heart valves (infective endocarditis)
  • People born with a structural heart defect (congenital heart disease)
  • People whose heart condition developed around the time of childbirth (peripartum cardiomyopathy)
  • People with active inflammation of the heart muscle or the sac surrounding the heart (confirmed by specific tests including heart tissue sampling or a special type of heart scan)
  • People with persistent, uncontrolled rapid heart rhythm problems
  • People with a long history of very heavy alcohol use (more than 80 grams per day for at least five years)
  • People who have had certain types of chemotherapy (anthracycline-based) at high cumulative doses
  • People with a history of very high blood pressure that was not well controlled
  • People with severely reduced kidney function (based on a specific kidney function calculation)
  • People with a known allergy or other medical reason to avoid the dye used in imaging procedures or the medication adenosine
  • People whose blood oxygen levels are persistently very low at rest
  • People who are pregnant or may be pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Roberto Scarsini, MD PhD, Azienda Ospedaliera Universitaria di Verona

Phone: 0039 0458122320

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Registry
ClinicalTrials.gov
Start date
3 January 2024
Est. completion
31 January 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Rate of Left ventricular reverse remodeling (LVRR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov